Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,425
EGF–ERBB signalling: towards the systems level
Citri, A., & Yarden, Y. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1962 · Cited by 2,004
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Bendell, J. C., Domchek, S. M., Burstein, H. J., Harris, L., Younger, J., Kuter, I., Bunnell, C., Rue, M., Gelman, R., & Winer, E. (2003) · Cancer · doi:10.1002/cncr.11436 · Cited by 1,320
Konecny, G. E., Pegram, M. D., Venkatesan, N., Finn, R., Yang, G., Rahmeh, M., Untch, M., Rusnak, D. W., Spehar, G., Mullin, R. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1182 · Cited by 914
Scaltriti, M., Rojo, F., Ocana, A., Anido, J., Guzman, M., Cortes, J., Di Cosimo, S., Matias-Guiu, X., Ramon y Cajal, S., Arribas, J., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk134 · Cited by 895
Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)
Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D., & Pollak, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1852 · Cited by 882
Cameron, D., Casey, M., Press, M., Lindquist, D., Pienkowski, T., Romieu, C. G., Chan, S., Jagiello-Gruszfeld, A., Kaufman, B., Crown, J., et al. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9885-0 · Cited by 794
Rusnak, D. W., Lackey, K. E., Affleck, K., Wood, E. R., Alligood, K. J., Rhodes, N., Keith, B. R., Murray, D. M., Knight, W. B., Mullin, R. J., et al. (2001) · PubMed · Cited by 728
Burris, H. A., Hurwitz, H. I., Dees, E. C., Dowlati, A., Blackwell, K. L., O'Neil, B., Marcom, P. K., Ellis, M. J., Overmoyer, B., Jones, S. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.16.584 · Cited by 619
ErbB receptors: from oncogenes to targeted cancer therapies
Zhang, H., Berezov, A., Wang, Q., Zhang, G., Drebin, J., Murali, R., & Greene, M. I. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32278 · Cited by 574
Knowlden, J. M., Hutcheson, I. R., Jones, H. E., Madden, T., Gee, J. M. W., Harper, M. E., Barrow, D., Wakeling, A. E., & Nicholson, R. I. (2003) · Endocrinology · doi:10.1210/en.2002-220620 · Cited by 521
Lin, N. U., Carey, L. A., Liu, M. C., Younger, J., Come, S. E., Ewend, M., Harris, G. J., Bullitt, E., Van den Abbeele, A. D., Henson, J. W., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3588 · Cited by 456
Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials
Perez, E. A., Koehler, M., Byrne, J., Preston, A. J., Rappold, E., & Ewer, M. S. (2008) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60896-3 · Cited by 388
Spector, N. L., Xia, W., Burris, H., Hurwitz, H., Dees, E. C., Dowlati, A., O'Neil, B., Overmoyer, B., Marcom, P. K., Blackwell, K. L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.157 · Cited by 362
Lichter, A. S., Lippman, M. E., Danforth, D. N., d'Angelo, T., Steinberg, S. M., deMoss, E., MacDonald, H. D., Reichert, C. M., Merino, M., & Swain, S. M. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.6.976 · Cited by 347
Gomez, H. L., Doval, D. C., Chavez, M. A., Ang, P. C.-S., Aziz, Z., Nag, S., Ng, C., Franco, S. X., Chow, L. W. C., Arbushites, M. C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.0590 · Cited by 338
Pestalozzi, B. C., & Brignoli, S. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.11.2349 · Cited by 301
Nahta, R., Yuan, L. X. H., Du, Y., & Esteva, F. J. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0423 · Cited by 267
Agulnik, M., Cohen, E. W. E., Cohen, R. B., Chen, E. X., Vokes, E. E., Hotte, S. J., Winquist, E., Laurie, S., Hayes, D. N., Dancey, J. E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.8612 · Cited by 263
Her-2/neu as a Predictive Marker of Response to Breast Cancer Therapy
Pegram, M. D., Pauletti, G., & Slamon, D. J. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1006111117877 · Cited by 259
Xia, W., Gerard, C. M., Liu, L., Baudson, N. M., Ory, T. L., & Spector, N. L. (2005) · Oncogene · doi:10.1038/sj.onc.1208774 · Cited by 258
Chu, I., Blackwell, K., Chen, S., & Slingerland, J. (2005) · Cancer Research · doi:10.1158/0008-5472.18.65.1 · Cited by 251
Biology of Interactions: Antiepidermal Growth Factor Receptor Agents
Harari, P. M., Allen, G. W., & Bonner, J. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.8984 · Cited by 214
Cardiotoxicity Profile of Trastuzumab
Ewer, S. M., & Ewer, M. S. (2008) · Drug Safety · doi:10.2165/00002018-200831060-00002 · Cited by 206
Burstein, H. J., Storniolo, A. M., Franco, S., Forster, J., Stein, S., Rubin, S., Salazar, V. M., & Blackwell, K. L. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm601 · Cited by 203
Johnston, S., Trudeau, M., Kaufman, B., Boussen, H., Blackwell, K., LoRusso, P., Lombardi, D. P., Ben Ahmed, S., Citrin, D. L., DeSilvio, M. L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9949 · Cited by 195
Rusnak, D. W., Alligood, K. J., Mullin, R. J., Spehar, G. M., Arenas‐Elliott, C., Martin, A. ‐., Degenhardt, Y., Rudolph, S. K., Jr Haws, T. F., Hudson‐Curtis, B. L., et al. (2007) · Cell Proliferation · doi:10.1111/j.1365-2184.2007.00455.x · Cited by 168
Petrov, K. G., Zhang, Y.-M., Carter, M., Cockerill, G. S., Dickerson, S., Gauthier, C. A., Guo, Y., Mook, R. A., Rusnak, D. W., Walker, A. L., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.05.090 · Cited by 166
Bence, A. K., Anderson, E. B., Halepota, M. A., Doukas, M. A., DeSimone, P. A., Davis, G. A., Smith, D. A., Koch, K. M., Stead, A. G., Mangum, S., et al. (2004) · Investigational New Drugs · doi:10.1023/b:drug.0000047104.45929.ea · Cited by 122
Storniolo, A. M., Pegram, M. D., Overmoyer, B. A., Silverman, P., Peacock, N. W., Jones, S. F., Loftiss, J., Arya, N., Koch, K. M., Paul, E. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.5202 · Cited by 121
Perez-Soler, R. (2006) · Clinical Lung Cancer · doi:10.3816/clc.2006.s.008 · Cited by 110
Ravaud, A., Hawkins, R., Gardner, J. P., von der Maase, H., Zantl, N., Harper, P., Rolland, F., Audhuy, B., Machiels, J.-P., Pétavy, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5029 · Cited by 105
Lessons from the Drug Discovery of Lapatinib, a Dual ErbB1/2 Tyrosine Kinase Inhibitor
Lackey, K. E. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606776743156 · Cited by 92
(2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-11-cor3 · Cited by 90
Analysis of dermatologic events in patients with cancer treated with lapatinib
Lacouture, M. E., Laabs, S., Koehler, M. T., Sweetman, R. W., Preston, A. J., Leo, A. D., Gómez, H., Salazar, V., Byrne, J., Koch, K. M., et al. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0020-7 · Cited by 89
Targeting the HER-kinase axis in cancer
Gross, M. E., Shazer, R. L., & Agus, D. B. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.01.005 · Cited by 79
Chu, Q. S.-C., Cianfrocca, M. E., Goldstein, L. J., Gale, M., Murray, N., Loftiss, J., Arya, N., Koch, K. M., Pandite, L. N., Fleming, R. A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4417 · Cited by 70
Phase I and Pharmacokinetic Study of Lapatinib and Docetaxel in Patients With Advanced Cancer
LoRusso, P. M., Jones, S. F., Koch, K. M., Arya, N., Fleming, R. A., Loftiss, J., Pandite, L., Gadgeel, S., Weber, B. L., & Burris, H. A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9633 · Cited by 68
Chu, Q. S.-C., Schwartz, G. H., Bono, J. S. D., Smith, D. A., Koch, K. M., Versola, M., Pandite, L., Arya, N., Curtright, J., Fleming, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.1765 · Cited by 61
Midgley, R. S., Kerr, R. S., Flaherty, K. T., Stevenson, J. P., Pratap, S., Koch, K. M., Smith, D. A., Versola, M., Fleming, R. A., Ward, C., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm366 · Cited by 56
Siegel-Lakhai, W. S., Beijnen, J. H., Vervenne, W. L., Boot, H., Keessen, M., Versola, M., Koch, K. M., Smith, D. A., Pandite, L. N., Richel, D. J., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0004 · Cited by 50
Cited by
Ross, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., & Hortobagyi, G. N. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0230 · Cited by 1,144
Targeting the EGFR signaling pathway in cancer therapy
Seshacharyulu, P., Ponnusamy, M. P., Haridas, D., Jain, M., Ganti, A. K., & Batra, S. K. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.648617 · Cited by 913
Clinical pharmacokinetics of tyrosine kinase inhibitors
van Erp, N. P., Gelderblom, H., & Guchelaar, H.-J. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.08.004 · Cited by 503
STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review
Qin, J.-J., Yan, L., Zhang, J., & Zhang, W.-D. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1206-z · Cited by 396
Targeted therapeutic options and future perspectives for HER2-positive breast cancer
Wang, J., & Xu, B. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0069-2 · Cited by 393
Metadata
- Authors
- MEDINA, P., & GOODIN, S.
- Venue
- Clinical Therapeutics
- Publisher
- Elsevier BV
- Published
- 2008-08
- Volume
- 30
- Issue
- 8
- Pages
- 1426-1447
- ISSN
- 0149-2918 (ISSN-L)
- OpenAlex
- W2067114310
- Cited by
- 377
- References
- 45
- FWCI
- 11.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.